Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity & Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Bio Farma) Adjuvanted With Alum+CpG 1018 Compared to Registered Covid-19 Vaccine (Covovax - Protein Subunit Vaccine) in Healthy Populations Aged 18 Years and Above in Indonesia (Phase III)

NCT05433285 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT05433285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05433285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity & Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Bio Farma) Adjuvanted With Alum+CpG 1018 Compared to Registered Covid-19 Vaccine (Covovax - Protein Subunit Vaccine) in Healthy Populations Aged 18 Years and Above in Indonesia (Phase III)
Lead sponsor
PT Bio Farma
Phase
Phase 3
Overall status
Completed
Start date
June 7, 2022
Completion date
August 31, 2023
Enrollment
4,050 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19